Two tests and one reference [General Sta­tis­tics]

posted by ElMaestro  – Denmark, 2020-08-31 12:23 (1755 d 06:50 ago) – Posting: # 21896
Views: 10,196

Hi Brus,

❝ If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?


❝ In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).


❝ If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?


❝ Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?


Here's a different way to look at it:
Can the same patient(s) be affected by your two tests? If yes, it is safer to use correction. If no, no correction should be necessary.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
58 visitors (0 registered, 58 guests [including 13 identified bots]).
Forum time: 19:13 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5